Mouse monoclonal anti-p40 [BC28] demonstrated similar sensitivity and specificity as the rabbit polyclonal p40, staining 97% (65/67) of cases of lung squamous cell carcinoma (SqCC) and 0% (0/71) cases of lung adenocarcinoma (ADC), in an in-house study. The monoclonal also has significantly less background and does not stain macrophages.

The mouse monoclonal anti-p40 [BC28] was developed by Biocare Medical through an intensive effort to identify an anti-p40 clone with superior staining performance. p40 (M) [BC28] is available exclusively from Biocare Medical and its worldwide network of distributors (Patent pending).

p40 may have applications in cases where p63 has traditionally been used as an IHC marker. In studies, the polyclonal p40 was equivalent to p63 [4A4] in sensitivity for lung SqCC, but p40 exhibited superior specificity by staining fewer lung ADC cases.1-3. p40 with TTF-1 improves specificity for SqCC vs. ADC, while preserving limited tissue specimens.3,4

Studies show equal sensitivity & superior specificity vs. p63 1

p40 with TTF-1 improves specificity for SqCC vs. ADC 3,4

Expression changes noted in bladder, prostate & breast cancers 5-8

<table>
<thead>
<tr>
<th>Ordering Information</th>
<th>Concentrate</th>
<th>Predilute</th>
<th>VP</th>
</tr>
</thead>
<tbody>
<tr>
<td>p40&lt;sup&gt;&lt;i&gt;TM&lt;/i&gt;&lt;/sup&gt; Antibody</td>
<td>ACI 3066 A, C</td>
<td>API 3066 AA</td>
<td>AVI 3066 KG</td>
</tr>
</tbody>
</table>

www.biocare.net